Prescription medicine
Ciprofloxacin and hydrocortisone Brand names: Cipro; first approved as Cipro Hc
Ciprofloxacin and hydrocortisone (Cipro) is a prescription medicine with an FDA approval on record since 1998. FDA's NDC Directory lists it from 1 generic labeler, and pharmacies paid $26.91 per mL (Ciprofloxacin-hydrocort 0.2-1%) in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the ciprofloxacin and hydrocortisone FDA label on DailyMed (effective May 29, 2026, Sandoz Inc); the NDA 20805 record on Drugs@FDA; every ciprofloxacin and hydrocortisone label on DailyMed.
Highlights of the record
FDA label of May 29, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageCiprofloxacin hydrochloride and hydrocortisone otic suspension is indicated for the treatment of acute otitis externa in adult and pediatric patients, one year and older, due to susceptible strains of Pseudomonas aeruginosa, Staphylococcus aureus, and Proteus mirabilis.
Forms and strengths
- 2 mg/ml / 10 mg/ml
Suspension/ drops.
On the market
- Earliest approval on file
- February 10, 1998 Cipro Hc, Sandoz; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 1 first November 10, 2025; 1 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 4 of which 1 under generic applications, 3 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $26.91 per mL Ciprofloxacin-hydrocort 0.2-1%
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 20,676 through July 30, 2026
What is ciprofloxacin and hydrocortisone used for?
From the label: indications and usageCiprofloxacin hydrochloride and hydrocortisone otic suspension is indicated for the treatment of acute otitis externa in adult and pediatric patients, one year and older, due to susceptible strains of Pseudomonas aeruginosa, Staphylococcus aureus, and Proteus mirabilis.
FDA pharmacologic class: Corticosteroid, Fluoroquinolone Antibacterial and Quinolone Antimicrobial.
Source: FDA drug label (ciprofloxacin hydrochloride and hydrocortisone), Sandoz Inc, effective May 29, 2026 (SPL set c0881bbe-cc95-45d4-9878-3bc8946eff26), via openFDA; the full label on DailyMed
Is there a generic for ciprofloxacin and hydrocortisone (Cipro)?
The FDA approved the first generic ciprofloxacin and hydrocortisone on November 10, 2025. 1 generic application is approved; 1 of it carries a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists ciprofloxacin and hydrocortisone from 1 labeler under a generic (ANDA) application and from 3 brand labelers. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 1998 earliest approval on file
- 2025 first generic approved
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for ciprofloxacin and hydrocortisone (Cipro)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $26.91 per mL (Ciprofloxacin-hydrocort 0.2-1%). The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Ciprofloxacin-hydrocort 0.2-1% (generic)
- Cipro hc ear suspension (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Ciprofloxacin-hydrocort 0.2-1% | Generic | $26.91 per mL | n/a | n/a |
| Cipro hc ear suspension | Brand | $34.93 per mL | n/a | +0.1% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What do FAERS reports show for ciprofloxacin and hydrocortisone?
The FDA Adverse Event Reporting System holds 20,676 reports that list ciprofloxacin and hydrocortisone among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 1,436 are coded as a death and 6,029 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Reports rose sharply in 2016 (2,846, against a median of 870 a year): FAERS counts follow reporting, which news, litigation and label changes can drive, not how often a reaction happens.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other corticosteroids
- the pharmacologic class, with prices and generics
- Ciprofloxacin and hydrocortisone side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other